Background. Recently antiangiogenic therapy with bevacizumab has shown a high but transient efficacy in glioblastoma (GBM). Indeed, GBM is one of the most angiogenic human tumors and endothelial proliferation is a hallmark of the disease. We therefore hypothesized that tumor cells may participate in endothelial proliferation of GBM. Materials and Methods. We used EGFR FISH Probe to detect EGFR amplification and anti-CD31, CD105, VE-cadherin, and vWF to identify endothelial cells. Endothelial and GBM cells were grown separately, labeled with GFP and DsRed lentiviruses, and then cocultured with or without contact. Results. In a subset of GBM tissues, we found that several tumor endothelial cells carry EGFR amplification, characteristic of GBM tumor cells. This observation was reproduced in vitro: when tumor stem cells derived from GBM were grown in the presence of human endothelial cells, a fraction of them acquired endothelial markers (CD31, CD105, VE-cadherin, and vWF). By transduction with GFP and DsRed expressing lentiviral vectors, we demonstrate that this phenomenon is due to cell fusion and not transdifferentiation. Conclusion. A fraction of GBM stem cells thus has the capacity to fuse with endothelial cells and the resulting hybrids may participate in tumor microvascular proliferation and in treatment resistance.
Introduction
Glioblastomas (GBM) are the most frequent and malignant primary brain tumors in adults with poor prognosis despite surgery and conventional radio-chemotherapy. Histologically, GBM are highly angiogenic and characterized by microvascular proliferations (previously called endothelial cell proliferations) typically consisting on multilayered tufts of mitotically active endothelial cells together with smooth muscle cells and pericytes [1] . Among targeted therapies tested to date, only antiangiogenic drugs and particularly anti-VEGF have shown efficacy with a nearly 50% of responders [2, 3] . However, this effect is always transient suggesting that GBM can acquire secondary antiangiogenic resistance. Therefore, understanding tumor endothelial cell abnormalities is important to optimize therapy. It is well established that tumor blood vessels differ from normal vessels by altered morphology, blood flow, permeability, and basement membrane deposition [4] [5] [6] [7] . Furthermore, evidence indicates that tumor endothelial cells overexpress specific genes, proliferate rapidly, and are sensitive to growth factors and resistant to chemotherapeutic drugs [8] [9] [10] [11] [12] . Surprisingly, tumor endothelial cells can harbor the same chromosomal abnormality as tumor cells in B-cell lymphomas [13] , multiple myeloma [14] , and neuroblastoma [15] , suggesting a tumor origin of at least a fraction of intratumoral endothelial cells.
Another subpopulation of tumor cells possesses characteristics associated with normal stem cells, specifically the ability to give rise to all cell types found in a particular cancer sample [16] . In brain tumors, including GBM, tumor stem cells have been shown to possess marked capacity for proliferation, self-renewal, and differentiation into all neural lineages [17] . It has also been suggested that normal mouse neural stem cells cocultured with human endothelial cells convert into endothelial cells by transdifferentiation [18] .
We here investigated whether endothelial cells of tumor origin might be present in human GBM samples and whether these cells derive from GBM stem cells. Analysis of EGFR amplified human GBM tissues by fluorescent in situ hybridization (FISH) combined with immunophenotyping [15] showed rare endothelial cells exhibiting EGFR amplification. We then investigated the capacity of GBM stem cells (GSC) to acquire an endothelial phenotype in vitro and demonstrate that this property results from cell fusion and not transdifferentiation.
Materials and Methods

GBM Tissue Preparation.
Formalin-fixed, paraffin-embedded tissue sections (5 m) from 10 GBM tumors (World Health Organization classification of brain tumors [1] ) carrying EGFR amplification identified by CGHa analysis [19] were deparaffinized twice with xylene. The slides were subsequently rehydrated in a series of ethanol solution (100%, 90%, and 70%), washed with phosphate-buffered saline (PBS), and treated with antigen retrieval solution (citrate buffer pH 9.0; Dako Cytomation, France) at 96 ∘ C for 20 minutes. Pierre Olivier Couraud (Institut Cochin, France). Endothelial cells were cultured with endothelial cell growth medium EGM-2 (Lonza, France) that contains vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), insulin growth factor I (IGF-I), hydrocortisone, ascorbic acid, and 2% fetal bovine serum.
Fluorescent In Situ
Differentiation Assay of Tumor Spheres.
Primary GBM spheres were plated onto sterile multiwell glass slide coated with poly-L-ornithine (Sigma-Aldrich, France) in neurosphere medium lacking EGF and bFGF but supplemented with 10% fetal bovine serum. Cells were fixed after 7 days of differentiation culture with 4% paraformaldehyde for 15 minutes, blocked with PBS/3% BSA for 20 minutes, and immunostained for 1 hour with primary antibodies against nestin (1 : 200; mouse monoclonal IgG1; Santa Cruz Biotechnology, Germany), GFAP (1 : 400; rabbit polyclonal; Dako Cytomation, France), and neuronal class III -tubulin (Tuj1; 1 : 500; mouse monoclonal IgG2a; Covance, France). After washes, appropriate secondary antibodies were incubated for 1 hour (1 : 1000; Alexa 594 goat anti-mouse IgG1, Alexa 488 goat anti-rabbit and Alexa 594 goat anti-mouse IgG2a from Molecular Probes, Invitrogen, France). DAPI (SigmaAldrich, France) was used for nuclei staining. Slides were mounted in antifade medium Fluoromount-G (Interchim, France) and examined under a Zeiss AxioImager.Z1 microscope.
Endothelial and GBM Cells Cocultures
Noncontact Coculture.
Cocultures were prepared on Transwell inserts with 0.4 m pore size and 6.5 mm diameter (Corning Incorporated, France) placed in 24 well plates. Briefly, GFP-GSC (p3) were seeded at 2 × 10 4 cells per well in the bottom wells of Transwells, and human endothelial cells were seeded at a ratio of 1 : 1 in the membrane insert wells. Cells were cultured with EGM-2 medium for 5 days. Cell layer fractions were analyzed using Nikon Eclipse TE2000U fluorescence inverted microscope.
Direct Contact Coculture. Dissociated human endothelial cells (5 × 10
5 ) and GFP-GSC (5 × 10 5 ) were mixed in EGM-2 medium and seeded into T75 flask. After 3 days of culture, cells were dissociated, plated onto sterile multiwell glass slides (1 × 10 4 on an 8-well slide), and allowed to adhere for 24 hours prior to staining.
Endothelial Markers
Immunofluorescence. After 3-5 days, coculture medium was washed away for 10 minutes with PBS before fixation with 4% paraformaldehyde for 15 minutes. Fixed cells were blocked with PBS/3% BSA for 20 minutes and permeabilized for intracytoplasmic antigen with PBS/0.1% Triton X-100. The following primary antibodies were incubated in blocking solution at room temperature for 1 hour: CD31 (1 : 50; mouse monoclonal IgG1; Dako Cytomation, France), CD105 (1 : 5; mouse monoclonal IgG1; Dako Cytomation, France), VE-cadherin (1 : 50; mouse monoclonal IgG1; eBioscience, France), and vWF (1 : 50; mouse monoclonal IgG1; Dako Cytomation, France). Following 3 washes, Alexa 594 goat anti-mouse IgG (1 : 1000; Molecular Probes, Invitrogen, France) was incubated in blocking solution at room temperature for 1 hour as secondary antibody. Nuclei were stained with DAPI (Sigma-Aldrich, France). Slides were mounted in antifade medium Fluoromount-G (Interchim, France) and examined under a Zeiss AxioImager.Z1 microscope. Fluorescence images were captured using AxioCam MRm camera and analyzed with AxioVision Rel. 4.6 software (Carl Zeiss).
Lentiviral
Infection. GFP and DsRed lentivirus vector construction and virus production were performed by Dr. Philippe Ravassard (Pierre and Marie Curie University) as previously described [20] . Dissociated GSC were infected with GFP-expressing retroviral vector and HUVEC were infected with DsRed-expressing retroviral vector. Labeled cells were selected using a fluorescence-activated cell sorter (FACS Aria, BD Biosciences). The efficiency of transduction was over 80%. 
Results
Several Intratumoral Endothelial Cells Harbor EGFR
Amplification. We analyzed paraffin sections from 10 GBM with EGFR amplification, retrieved from our CGHa database [19] , using CD31 monoclonal antibody to identify endothelial cells and FISH detection of EGFR amplification to identify tumor cells. As shown in Figure 1(a) , EGFR amplification was detected as double minutes by red hybridization signals in a large proportion of cells present in GBM tissues. CD31 monoclonal antibody stained endothelial cells but not tumor cells (Figure 1(b) ). Only 6 out of 10 GBM sections presented dense microvascular network with high morphologic quality after CD31 immunofluorescence and were then subjected to EGFR FISH. Endothelial cells carrying EGFR amplification, as shown in Figures 1(c) and 1(d) , were identified in 3 out of these 6 GBM tumors. This event was episodic as we were able to count less than a hundred of CD31-EGFR FISH costained cells per section. Thus, we identified a minority of tumor endothelial cells that could derive from primary GBM cells.
Glioblastoma Stem Cells Acquire an Endothelial Phenotype When Cocultured with Human Endothelial Cells.
We established 3 GBM stem cell primary cultures (GSC-1, GSC-2, and GSC-3) that demonstrated growth into tumor spheres (Figure 2(a) ). They were generated from solid primary adult GBMs carrying EGFR amplification and showed conservative genomic profile in culture (Figure 2(b) ). Undifferentiated tumor spheres immunostained for nestin (a characteristic neural stem cell marker) and revealed multilineage potential (expression of GFAP for astrocytes and TUJ-1 for neurons) in the differentiation assay as shown in Figure 2 VE-cadherin endothelial markers even after growth in EGM-2 medium, known to promote endothelial differentiation [21] ( Figure 2(c) ).
To test the hypothesis that GSC might need a more specific microenvironment for endothelial conversion, we cocultured GSC-GFP with different human endothelial cells (HUVEC, HUAEC, and hCMEC) allowing cell-cell contact. In this condition, some GSC-GFP exhibited cobblestone morphology and expressed specific endothelial markers including CD31, CD105, VE-cadherin, and vWF (Figure 3(a) ). The endothelial-like GSC-GFP were found consistently, but their percentage was variable (0.2% to 1%) depending on the GSC and the endothelial cell types used in direct coculture (Figure 3(b) ). However, this conversion was not observed in noncontact coculture, suggesting the implication of cell fusion or cell contact factors.
Some Glioblastoma Stem Cells Acquire the Endothelial Phenotype through Cell Fusion.
The fact that most endothelial-like tumor cells were multinucleated suggested that GSC may acquire endothelial phenotype through cell fusion, rather than cell transdifferentiation. To test this hypothesis, we used DsRed protein-expressing HUVEC to detect cell fusion in fluorescent microscopy. When GSC-GFP were cocultured with HUVEC-DsRed, binucleated cells coexpressing both GFP and DsRed were observed (Figure 4(a), (A)-(C) ). GFP+/DsRed+ fused cells maintained CD31 expression (Figure 4(a), (D) ), meaning that the endothelial phenotype was dominant. We isolated the GFP+/DsRed+ cells by cell sorting and cultured them in EGM-2 medium to monitor their behavior over time. Most of these cells with heterocaryons were quiescent and died after 5 to 7 days of culture. A small fraction (less than 1%) gave rise to viable mononuclear hybrids expressing the parental GFP and DsRed, as shown in Figure 4 (b).
Discussion
As early as 1948, several observations suggested that cancer cells are located in the walls of tumor blood vessels and participate in their assembly [22, 23] . This is known as "mosaic vessels" where tumor cells form a part of the vessel surface, while the remaining part is covered by endothelium [24] . But in this case, tumor cells in apparent contact with the lumen do not show an endothelial phenotype. We report here that human GBM contain some tumor endothelial cells carrying the same cytogenetic abnormality as tumor cells. This phenomenon was reported previously in B-cell lymphomas [13] , multiple myeloma [14] , and neuroblastoma [15] . Since a common precursor can give rise to hematopoietic lineage and endothelial cells in hematopoietic tumors, a common progenitor targeted by neoplastic transformation and sharing specific genetic abnormalities can differentiate into tumor cells or endothelial cells [13, 14] . This hypothesis is not applicable to solid tumors of nonhematopoietic origin. Alternative explanations include tumor microenvironment [ 25, 26] , tumor cell transdifferentiation, and cell fusion [27] . Our data strongly suggest that GBM stem cell acquires endothelial phenotype through cell fusion and participates in microvascular structures. This is consistent with a recent study in which human glioma lines marked with DsRed protein were grafted in eGFP-expressing NOD/Scid mouse to study tumor-host interactions [28] . Using fluorescence-activated cell sorting (FACS), this model is allowed to completely separate host cells from tumor cells and to detect double-positive cells, possibly arising from cell fusion events. Furthermore, CD31 expression was found in 0.3% of separated tumor cells when phenotyped [28] . In normal brain, neural stem cells exist in vascular niches where endothelial cells provide direct cell contacts and secreted factors that regulate neural stem cell function [29, 30] . Similarly, GBM stem cells are maintained within vascular niches that mimic the neural stem cell niche [31] . Nestin+/CD133+ cells within sections of human GBM are located in close proximity to tumor capillaries [31] . This organization can favor cell fusion by facilitating cell contact between GBM stem cells and endothelial cells. Cell fusion has been debated in adult stem cells plasticity. Several reports revealed the ability for stem cells to change fate through cell fusion rather than cell transdifferentiation. New hybrids resulting from nuclear fusion can generate mononuclear differentiated progeny that exhibit both parental phenotypes [18, [32] [33] [34] [35] . These findings raise the possibility that cell fusion has undiscovered functions which can promote disease, especially cancer. The idea that cell fusion contributes to cancer progression was introduced almost 100 years ago with a proposal that malignancy is a consequence of hybridization between leukocytes and somatic cells [36] . Sixty years later, this idea was expanded by proposing that hybridization of tumor cells with lymphocytes results in metastatic cells [37] and that cell fusion promotes the phenotypic and genotypic diversity of tumors [38] . The best defended theory is cancer cell fusion with macrophages or other migratory bone marrow-derived cells which provides a unifying explanation for metastasis [39] . Although host cell-cancer cell fusion has been demonstrated and well documented in animals [40] , there is as yet far less information on human cancer. A few human cases have recently been reported [41] [42] [43] [44] [45] , but it is unclear whether the scarcity of reports on cell fusion in human tumors is due to rarity of this event or to a difficulty to detect it.
In addition to cell fusion, we cannot exclude that transdifferentiation of GBM stem cells into endothelial cells may exist. Conversion from GBM to endothelial phenotype was not observed in noncontact coculture, suggesting either cell fusion or cell-cell contact mediated transdifferentiation. Recently two recent papers showed that transdifferentiation of GBM stem cells into endothelial cells does exist in GBM (p7). Notch pathway is involved in this mechanism [46] [47] [48] . Considering that cell fusion can be linked to several fundamental features of cancer, more investigations are needed to clarify this emergent concept of "hidden enemy" in cancer pathology. In addition, the presence of these hybrid cells in GBM endothelium supports new therapeutic approaches, such as intravascular targeted strategy directed against the EGFRVIII mutant, a specific antigen expressed by 20-30% of GBM [49] .
